Boston Scientific’s Watchman left atrial appendage (LAA) closure device to prevent stroke resulted in significantly less bleeding after an ablation procedure than taking blood thinners ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...

Additionally, the Watchman FLX is expected to benefit from future updates in labeling and reimbursement, which could further drive its adoption. Boston Scientific’s electrophysiology (EP ...

Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical ...

Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. Check out why ...

The deal for Bolt, developer of an intravascular lithotripsy system to treat coronary and peripheral artery disease, ...

Boston Scientific Corporation (NYSE ... year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.